These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 2889795)
1. Central action of ipsapirone, a new anxiolytic drug, on serotoninergic, noradrenergic and dopaminergic functions. Maj J; Chojnacka-Wójcik E; Tatarczyńska E; Kłodzińska A J Neural Transm; 1987; 70(1-2):1-17. PubMed ID: 2889795 [TBL] [Abstract][Full Text] [Related]
2. The central action of 1-(2-pyrimidinyl)-piperazine, an ipsapirone metabolite. Tatarczyńska E; Pawłowski L; Chojnacka-Wójcik E; Maj J Pol J Pharmacol Pharm; 1989; 41(1):51-61. PubMed ID: 2587437 [TBL] [Abstract][Full Text] [Related]
3. Alterations of central serotonin and dopamine turnover in rats treated with ipsapirone and other 5-hydroxytryptamine1A agonists with potential anxiolytic properties. Hamon M; Fattaccini CM; Adrien J; Gallissot MC; Martin P; Gozlan H J Pharmacol Exp Ther; 1988 Aug; 246(2):745-52. PubMed ID: 2457083 [TBL] [Abstract][Full Text] [Related]
4. Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studies. Schechter LE; Bolaños FJ; Gozlan H; Lanfumey L; Haj-Dahmane S; Laporte AM; Fattaccini CM; Hamon M J Pharmacol Exp Ther; 1990 Dec; 255(3):1335-47. PubMed ID: 1702155 [TBL] [Abstract][Full Text] [Related]
6. Subchronic treatment with anxiolytic doses of the 5-HT1A receptor agonist ipsapirone does not affect 5-HT2 receptor sensitivity in the rat. Baudrie V; De Vry J; Broqua P; Schmidt B; Chaouloff F; Glaser T Eur J Pharmacol; 1993 Feb; 231(3):395-406. PubMed ID: 8095465 [TBL] [Abstract][Full Text] [Related]
7. Response of cerebellar Purkinje cells to serotonin and the 5-HT1A agonists 8-OH-DPAT and ipsapirone in vitro. Darrow EJ; Strahlendorf HK; Strahlendorf JC Eur J Pharmacol; 1990 Jan; 175(2):145-53. PubMed ID: 1968842 [TBL] [Abstract][Full Text] [Related]
8. Effect of acute and chronic treatment of rats with the putative anxiolytic drug ipsapirone on the turnover of monoamine transmitters in various brain regions. A comparison with the 5-HT1A agonist 8-OH-DPAT. Gołembiowska K Pol J Pharmacol Pharm; 1992; 44(1):15-24. PubMed ID: 1359515 [TBL] [Abstract][Full Text] [Related]
9. Neuronal circuits involved in the anxiolytic effects of the 5-HT1A receptor agonists 8-OH-DPAT ipsapirone and buspirone in the rat. Schreiber R; De Vry J Eur J Pharmacol; 1993 Nov; 249(3):341-51. PubMed ID: 7904566 [TBL] [Abstract][Full Text] [Related]
10. The effects of a 5-HT1 receptor ligand isapirone (TVX Q 7821) on 5-HT synthesis and the behavioural effects of 5-HT agonists in mice and rats. Goodwin GM; De Souza RJ; Green AR Psychopharmacology (Berl); 1986; 89(3):382-7. PubMed ID: 2941817 [TBL] [Abstract][Full Text] [Related]
11. Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist. De Vry J; Schohe-Loop R; Heine HG; Greuel JM; Mauler F; Schmidt B; Sommermeyer H; Glaser T J Pharmacol Exp Ther; 1998 Mar; 284(3):1082-94. PubMed ID: 9495870 [TBL] [Abstract][Full Text] [Related]
12. Central antiserotonergic and antidopaminergic action of pirenperone, a putative 5-HT2 receptor antagonist. Pawłowski L; Siwanowicz J; Bigajska K; Przegaliński E Pol J Pharmacol Pharm; 1985; 37(2):179-96. PubMed ID: 4048012 [TBL] [Abstract][Full Text] [Related]
13. Evidence for the involvement of 5-HT1A receptors in the anticonflict effect of ipsapirone in rats. Chojnacka-Wójcik E; Przegaliński E Neuropharmacology; 1991 Jul; 30(7):703-9. PubMed ID: 1681448 [TBL] [Abstract][Full Text] [Related]
14. Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists. Meller E; Goldstein M; Bohmaker K Mol Pharmacol; 1990 Feb; 37(2):231-7. PubMed ID: 1968223 [TBL] [Abstract][Full Text] [Related]
15. A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors. Goodwin GM; Green AR Br J Pharmacol; 1985 Mar; 84(3):743-53. PubMed ID: 2580582 [TBL] [Abstract][Full Text] [Related]
16. Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat? Jolas T; Schreiber R; Laporte AM; Chastanet M; De Vry J; Glaser T; Adrien J; Hamon M J Pharmacol Exp Ther; 1995 Feb; 272(2):920-9. PubMed ID: 7853210 [TBL] [Abstract][Full Text] [Related]
17. Differential induction of 5-HT1A-mediated responses in vivo by three chemically dissimilar 5-HT1A agonists. Scott PA; Chou JM; Tang H; Frazer A J Pharmacol Exp Ther; 1994 Jul; 270(1):198-208. PubMed ID: 8035316 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats. Kleven MS; Assié MB; Koek W J Pharmacol Exp Ther; 1997 Aug; 282(2):747-59. PubMed ID: 9262338 [TBL] [Abstract][Full Text] [Related]
19. Anxiolytic effects of the 5-HT1A receptor agonist ipsapirone in the rat: neurobiological correlates. Sommermeyer H; Schreiber R; Greuel JM; De Vry J; Glaser T Eur J Pharmacol; 1993 Aug; 240(1):29-37. PubMed ID: 7691626 [TBL] [Abstract][Full Text] [Related]
20. [The presynaptic metabolic modulation of the impulse-dependent release of 3H-serotonin from rat brain slices by ipsapirone (TVX Q 7821) and other serotonin agonists]. Dolzhenko AT; Traber J; Glaser T; De Vry J Eksp Klin Farmakol; 1993; 56(4):9-12. PubMed ID: 8106062 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]